L Licitra

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. doi request reprint Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck
    Lisa Licitra
    Head and Neck Medical Oncology Unit, Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan 20133, Italy Electronic address
    Oral Oncol 52:18-23. 2016
  2. pmc Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
    Jean Pascal H Machiels
    Cancer Center, Service d Oncologie Medicale, Cliniques universitaires Saint Luc and Institut de Recherche Clinique et Expérimentale Pole MIRO, Universite Catholique de Louvain, Brussels, Belgium
    BMC Cancer 14:473. 2014
  3. doi request reprint Multikinase inhibitors in thyroid cancer
    Lisa Licitra
    Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
    Eur J Cancer 46:1012-8. 2010
  4. ncbi request reprint High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma
    Lisa Licitra
    Head and Neck Cancer Medical Oncology Unit, Medical Statistics and Biometry, Department of Head and Neck Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Clin Oncol 24:5630-6. 2006
  5. ncbi request reprint Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma
    L Licitra
    Medical Oncology Department, Head and Neck Unit, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    J Clin Oncol 22:4901-6. 2004
  6. doi request reprint Human papillomavirus in HNSCC: a European epidemiologic perspective
    Lisa Licitra
    Head and Neck Medical Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Hematol Oncol Clin North Am 22:1143-53, vii-viii. 2008
  7. ncbi request reprint Advances in the changing patterns of aetiology of head and neck cancers
    Lisa Licitra
    Head and Neck Cancer Medical Oncology Unit, Cancer Medicine Department, Istituto Nazionale Tumori, Milan, Italy
    Curr Opin Otolaryngol Head Neck Surg 14:95-9. 2006
  8. doi request reprint Targeted therapy in head and neck cancer
    Lisa Licitra
    Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy
    Curr Opin Otolaryngol Head Neck Surg 19:132-7. 2011
  9. ncbi request reprint Is there still a role for neoadjuvant chemotherapy in head and neck cancer?
    L Licitra
    Medical Oncology Unit, Head and Neck Department, Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 15:7-11. 2004
  10. ncbi request reprint Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial
    Lisa Licitra
    Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 21:327-33. 2003

Detail Information

Publications61

  1. doi request reprint Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck
    Lisa Licitra
    Head and Neck Medical Oncology Unit, Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan 20133, Italy Electronic address
    Oral Oncol 52:18-23. 2016
    ..How this information can be used to individualise treatment to optimise clinical outcomes, maximise the patient's day-to-day living and minimise healthcare spending in SCCHN is discussed. ..
  2. pmc Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
    Jean Pascal H Machiels
    Cancer Center, Service d Oncologie Medicale, Cliniques universitaires Saint Luc and Institut de Recherche Clinique et Expérimentale Pole MIRO, Universite Catholique de Louvain, Brussels, Belgium
    BMC Cancer 14:473. 2014
    ..Based on these observations, the Phase III, LUX-Head & Neck 1 study is evaluating afatinib versus methotrexate in R/M HNSCC patients following progression on platinum-based chemotherapy in the R/M setting...
  3. doi request reprint Multikinase inhibitors in thyroid cancer
    Lisa Licitra
    Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
    Eur J Cancer 46:1012-8. 2010
    ..To date no drug has proved to prolong survival, as such none of these agents has been approved...
  4. ncbi request reprint High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma
    Lisa Licitra
    Head and Neck Cancer Medical Oncology Unit, Medical Statistics and Biometry, Department of Head and Neck Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Clin Oncol 24:5630-6. 2006
    ..To which extent the viral integration by itself, and/or the associated wild-type (wt) TP53 status, and/or a functional p16 contribute to prognosis is unclear...
  5. ncbi request reprint Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma
    L Licitra
    Medical Oncology Department, Head and Neck Unit, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    J Clin Oncol 22:4901-6. 2004
    ..To assess the role of TP53 status in predicting pathologic complete remission after primary chemotherapy in patients with ethmoidal intestinal-type adenocarcinoma (ITAC)...
  6. doi request reprint Human papillomavirus in HNSCC: a European epidemiologic perspective
    Lisa Licitra
    Head and Neck Medical Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Hematol Oncol Clin North Am 22:1143-53, vii-viii. 2008
    ..Three-year survival rates improved more in human papillomavirus-related than unrelated cancer sites, and women had better rates of survival than men...
  7. ncbi request reprint Advances in the changing patterns of aetiology of head and neck cancers
    Lisa Licitra
    Head and Neck Cancer Medical Oncology Unit, Cancer Medicine Department, Istituto Nazionale Tumori, Milan, Italy
    Curr Opin Otolaryngol Head Neck Surg 14:95-9. 2006
    ..In fact, a review of the most recent literature shows interesting advances in molecular epidemiology...
  8. doi request reprint Targeted therapy in head and neck cancer
    Lisa Licitra
    Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy
    Curr Opin Otolaryngol Head Neck Surg 19:132-7. 2011
    ..Due to the unique multidisciplinary needs of the disease, it is of paramount importance that physicians who treat HNC are aware of the evolving changes that research is offering...
  9. ncbi request reprint Is there still a role for neoadjuvant chemotherapy in head and neck cancer?
    L Licitra
    Medical Oncology Unit, Head and Neck Department, Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 15:7-11. 2004
    ..This article reviews current indications for neoadjuvant chemotherapy in advanced head and neck cancer. Implications for current and future research are discussed...
  10. ncbi request reprint Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial
    Lisa Licitra
    Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 21:327-33. 2003
    ..Here we repeat the results of a randomized, multicenter trial enrolling patients with a resectable, stage T2-T4 (> 3 cm), N0-N2, M0 untreated, squamous cell carcinoma of the oral cavity...
  11. ncbi request reprint Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer
    L Licitra
    Unit of Medical Oncology A, Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 14:367-72. 2003
    ..To study prospectively the activity of primary chemotherapy with cisplatin, fluorouracil and leucovorin (PFL) in patients with paranasal cancer receiving surgery and postoperative radiotherapy...
  12. ncbi request reprint A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?
    Lisa Licitra
    Head and Neck Cancer Medical Oncology Unit, Cancer Medicine Department, Istituto Nazionale Tumori, Milan, Italy
    Curr Opin Oncol 18:253-7. 2006
    ..Due to the complexity of the disease the multidisciplinary approach needs also a multidisciplinary knowledge which this review tries to summarize...
  13. doi request reprint Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study
    R Granata
    Head and Neck Cancer Medical Oncology Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 23:1832-7. 2012
    ..Recently, three groups with different outcomes were identified based on HPV status, smoking history and tumor stage. Our objective was to validate this model using a single-institutional retrospective database...
  14. ncbi request reprint Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial
    L Licitra
    Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 8:1157-8. 1997
    ..Cisplatin is an active drug in head and neck cancer. Paclitaxel seems a promising drug. This article reports a phase II assessment of the combination of the two...
  15. doi request reprint Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer
    P Bossi
    Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, Milan, Italy
    Ann Oncol 22:2495-500. 2011
    ....
  16. doi request reprint TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma
    Federica Perrone
    Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
    J Clin Oncol 28:761-6. 2010
    ....
  17. ncbi request reprint TPF induction chemotherapy (CT) followed by concomitant cisplatin/radiotherapy (cCTRT) in locally advanced nasopharyngeal cancer (LANPC)
    P Bossi
    Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 27:6046. 2009
    ..In head and neck cancer, docetaxel, cisplatin and 5 FU (TPF) induction chemotherapy led to survival gain over cisplatin and 5FU alone. We studied feasibility and activity of TPF induction CT followed by cCTRT in LANPC...
  18. doi request reprint Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study
    L D Locati
    Head and Neck Cancer Medical Oncology Unit, Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
    Oral Oncol 45:574-8. 2009
    ..In RMSGCs further evaluations of EGFR targeting agents are advisable and should take place by appropriate tumor biological selection, differentiating ACC from non-ACC...
  19. ncbi request reprint A new classification for malignant tumors involving the anterior skull base
    G Cantu
    Unit of Cranio Maxillo Facial Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Arch Otolaryngol Head Neck Surg 125:1252-7. 1999
    ..To propose our clinical classification of malignant ethmoid tumors and to compare it with the last American Joint Committee on Cancer (AJCC)-Union Internationale Contre le Cancer (UICC) classification, published in 1997...
  20. doi request reprint Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options
    L Licitra
    Head and Neck Medical Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:vii200-3. 2008
  21. ncbi request reprint Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers
    A Costa
    Oncologia Sperimentale C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Int J Cancer 79:619-23. 1998
    ..02). This interim analysis appears to indicate that some biofunctional markers can provide information on pathological response to PCT and could help in understanding treatment efficacy at a cellular level...
  22. doi request reprint Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations
    A Mirabile
    Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy Electronic address
    Crit Rev Oncol Hematol 99:100-6. 2016
    ..External expert reviewers evaluated the final statements. The paper contains 30 consensus-reached statements about pain management in HNC patients and offers a review of recent literature in these topics. ..
  23. doi request reprint A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact
    L D Locati
    Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Electronic address
    Eur J Cancer 69:158-165. 2016
    ..e. BRAF, vascular endothelial growth factor receptor 2 [VEGFR2], platelet-derived growth factor receptor α [PDGFRα] and β, RET, KIT)...
  24. ncbi request reprint Biological agents in head and neck cancer
    L Licitra
    Istituto Nazionale dei Tumori, Head and Neck Medical Oncology Unit, Milan, Italy
    Ann Oncol 17:x45-8. 2006
  25. ncbi request reprint Treatment of cancer of the base of the tongue and glosso-epiglottic region: a multicenter Italian survey. GLOCC Group. Gruppo di Lavoro in Oncologia Cervico Cefalica
    C Grandi
    Division of Otorhinolaryngology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 86:215-23. 2000
    ..The purpose of our study was to evaluate the results of treatment in a large series of patients from 18 Italian institutions in relation to the main treatment adopted...
  26. ncbi request reprint Head and neck tumors other than squamous cell carcinoma
    Lisa Licitra
    Head and Neck Department, Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Curr Opin Oncol 16:236-41. 2004
    ..This review deals with classification and treatment of some rare nonsquamous cell carcinomas of the head and neck...
  27. ncbi request reprint TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses
    Federica Perrone
    Unit of Experimental Molecular Pathology, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Int J Cancer 105:196-203. 2003
    ..Given the important role that these genes play in cell growth control and apoptosis, the knowledge of ITAC genetic profile may be helpful in selecting more tailored treatments...
  28. ncbi request reprint Quality of life assessment and clinical decision-making
    P Casali
    Division of Medical Oncology A, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 8:1207-11. 1997
    ..Providing average quality of life scores may be useful, indeed, for population-based health decisions, as are those on resource allocation and those on registration of new drugs...
  29. ncbi request reprint Adenocarcinoma of ethmoid sinus: an occupational disease
    G Bimbi
    Head and Neck Surgery Department, National Cancer Institute, Milan, Italy
    Acta Otorhinolaryngol Ital 24:199-203. 2004
    ..No significant correlation was observed between exposure and either non-ethmoidal sinonasal neoplasms or ethmoidal tumours other than adenocarcinomas...
  30. pmc Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study
    L Licitra
    Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 22:1078-87. 2011
    ..The aim of this investigation was to evaluate elevated tumor EGFR gene copy number as a predictive biomarker in EXTREME study patients...
  31. ncbi request reprint Head and neck cancer
    L Licitra
    Head and Neck Cancer Medical Oncology Unit, Cancer Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 15:iv267-73. 2004
  32. doi request reprint Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients
    L Licitra
    Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 22:1886-93. 2011
    ..We studied the impact of processes triggered by HNSCC surgery in stimulating both residual tumor cells [demonstrated to overexpress epidermal growth factor receptor (EGFR)], and premalignant cells surrounding the resected lesion...
  33. doi request reprint Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience
    Mauro Palazzi
    Unit of Radiotherapy, Istituto Nazionale Tumori, Milan, Italy
    Int J Radiat Oncol Biol Phys 74:774-80. 2009
    ..To report the outcome of a consecutive series of patients with nonmetastatic nasopharyngeal carcinoma (NPC), focusing on the impact of treatment-related factors...
  34. doi request reprint Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status
    Carlo Fallai
    Radiation Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    Int J Radiat Oncol Biol Phys 75:1053-9. 2009
    ..To study the prognostic value of the TP53 mutation and human papilloma virus (HPV) status in oropharyngeal squamous cell carcinoma (OPSCC)...
  35. doi request reprint Survival from salivary glands adenoid cystic carcinoma in European populations
    Laura Ciccolallo
    Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
    Oral Oncol 45:669-74. 2009
    ..Improvements in the disease detection in its early stage and international collaborative research should be encouraged...
  36. ncbi request reprint Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma
    Federica Perrone
    Unit of Experimental Molecular Pathology, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Italy
    Clin Cancer Res 12:6643-51. 2006
    ....
  37. ncbi request reprint Biological agents in head and neck cancer
    Paolo Bossi
    Medical Oncology 3 Head and Neck Cancer Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1 20133 Milan, Italy
    Expert Rev Anticancer Ther 7:1643-50. 2007
    ..Molecular characteristics and treatment-relevant signaling pathways will be briefly discussed along with the results of the more recent clinical studies that include biological agents...
  38. ncbi request reprint Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system
    Mauro Palazzi
    Unit of Radiotherapy, Istituto Nazionale Tumori, Milan, Italy
    Int J Radiat Oncol Biol Phys 70:330-7. 2008
    ..0 (CTCAE v3.0), scoring system...
  39. ncbi request reprint p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx
    Federica Perrone
    Unit of Experimental Molecular Pathology, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 109:2461-5. 2007
    ..The TP53 polymorphism, in which an arginine (R) is changed to proline (P) at codon 72, is functionally significant and could therefore be a predisposing genetic defect...
  40. ncbi request reprint Phenotype-genotype correlation: challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses
    Milo Frattini
    Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Head Neck 28:909-15. 2006
    ..Our aim was to verify whether the morphologic resemblances mirror genetic profile similarities...
  41. ncbi request reprint Cancer of the nasopharynx
    Lisa Licitra
    START Project and Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Crit Rev Oncol Hematol 45:199-213. 2003
    ..Standard therapeutic option for early stages of NPC is radiation, while an integration of radiation therapy and chemotherapy is indicated in more advanced stages...
  42. ncbi request reprint Regionally advanced nasopharyngeal carcinoma: long-term outcome after sequential chemotherapy and radiotherapy
    Mauro Palazzi
    Department of Radiotherapy, National Cancer Institute, Milan, Italy
    Tumori 90:60-5. 2004
    ..To evaluate the long-term clinical outcome of 61 patients with regionally advanced nasopharyngeal carcinoma treated with sequential chemotherapy and radiotherapy within a phase II trial...
  43. ncbi request reprint Which classification for ethmoid malignant tumors involving the anterior skull base?
    Giulio Cantu
    Department of Head and Neck Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Head Neck 27:224-31. 2005
    ..The purpose of this study was to compare three systems of classification for malignant ethmoidal tumors in patients undergoing anterior craniofacial resection...
  44. ncbi request reprint Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland
    Laura D Locati
    Medical Oncology Unit Head and Neck Unit, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Oral Oncol 41:890-4. 2005
    ..Lung metastasectomy provided a prolonged FFP in a high selected subset of patients with ACC. However, if this could be translated into a survival benefit, it is still to be demonstrated...
  45. ncbi request reprint START: a European state-of-the-art on-line instrument for clinical oncologists
    P Casali
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 10:769-73. 1999
    ..The goal of instruments such as START is to improve the quality of patient care. In addition, START hopes to make contributions to the methodology by which medical research is transformed into clinical decisions...
  46. ncbi request reprint Primary high-grade mucoepidermoid carcinoma of the minor salivary glands with cutaneous metastases at diagnosis
    L D Locati
    Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy
    Oral Oncol 38:401-4. 2002
    ..This feature was associated with a chemoresistant and aggressive behaviour. Differential diagnosis between metastatic MEC and primary skin MEC is essential for therapeutic management and prognosis...
  47. ncbi request reprint Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN
    L Licitra
    Istituto Nazionale Tumori, Milan, Italy Centre René Gauducheau, Saint Herblain, France University Medical Center Hamburg Eppendorf, Hamburg, Germany National Institute of Oncology, Budapest, Hungary LBI ACR and ACR ITR Vienna KFJ Spital, Vienna, Austria HELIOS Klinikum Wuppertal, University Witten Herde, Wuppertal, Germany Merck KGaA, Darmstadt, Germany Institut Català d Oncologia, L Hospitalet, Barcelona, Spain
    J Clin Oncol 27:6005. 2009
    ..N Engl J Med 2008;359:1116-1127). A retrospective analysis has evaluated the influence of EGFR gene copy number, determined by FISH, on clinical outcome in the EXTREME study...
  48. doi request reprint Italian version of the M.D. Anderson Symptom Inventory--Head and Neck Module: linguistic validation
    A Greco
    Department of Psychology, University of Milan Bicocca, Milan, Italy
    Support Care Cancer 23:3465-72. 2015
    ..PRO instrument applicability and cultural adaptation must be tested for each population. The aim of this study is to linguistically validate the Italian translation of the M.D. Anderson Symptom Inventory--Head and Neck Module (MDASI-HN)...
  49. doi request reprint The burden of rare cancers in Europe
    Gemma Gatta
    Fondazione IRCCS Istituto Nazionale dei Tumori, Dipartimento di Medicina Predittiva e per la Prevenzione, Unità di Epidemiologia Valutativa, Via Venezian, 1, 20133, Milan, Italy
    Adv Exp Med Biol 686:285-303. 2010
    ..The burden indicators were estimated and are provided in this chapter...
  50. doi request reprint Major and minor salivary gland tumors
    Marco Guzzo
    Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Crit Rev Oncol Hematol 74:134-48. 2010
    ..Metastatic disease may be either treated with radiotherapy or palliative chemotherapy, depending on the site of metastases. For highly selected patients the employment of anti-androgen therapy is indicated...
  51. ncbi request reprint Cancer of the anal region
    Lisa Licitra
    START Project, European School of Oncology, Milan, Italy
    Crit Rev Oncol Hematol 43:77-92. 2002
    ..Long-term quality of life (QOL) scores are acceptable, with the exception of patients who experience severe anal dysfunction...
  52. doi request reprint Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM
    D Alterio
    Department of Radiotherapy, Advanced Radiotherapy Center, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Med Oncol 33:76. 2016
    ..Analysis of abovementioned results may give the chance to modify some clinical attitudes and create the background for future clinical investigation in this field. ..
  53. ncbi request reprint Major and minor salivary glands tumours
    Lisa Licitra
    START Project, European School of Oncology, Viale Beatrice d Este, 37, 20122, Milan, Italy
    Crit Rev Oncol Hematol 45:215-25. 2003
    ..Metastastic disease may be either treated with radiotherapy or palliative chemotherapy, depending on the site of metastases...
  54. ncbi request reprint Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer?
    Lisa Licitra
    J Clin Oncol 23:7757-8; author reply 7758-9. 2005
  55. ncbi request reprint Cisplatin and fluorouracil concurrent to radiotherapy in nasopharyngeal cancer: is the schedule compatible?
    Lisa Licitra
    J Clin Oncol 22:377; author reply 377-8. 2004
  56. ncbi request reprint Systemic therapy in the palliative management of advanced salivary gland cancers
    Scott A Laurie
    Ottawa Hospital Regional Cancer Centre, The University of Ottawa, Ottawa, Canada
    J Clin Oncol 24:2673-8. 2006
    ..There is a need for a determined, coordinated effort to conduct high-quality clinical trials in patients with these rare cancers...
  57. ncbi request reprint Forecasting the performance status of head and neck cancer patient treatment by an interval arithmetic pruned perceptron
    Gian Paolo Drago
    Istituto per i Circuiti Elettronici Consiglio Nazionale delle Ricerche, Genova, Italy
    IEEE Trans Biomed Eng 49:782-7. 2002
    ..This result should open a new perspective in the clinical approach, by supplying a potential predictive indicator for toxicity...
  58. ncbi request reprint TP53 mutations in head and neck cancer
    Federica Perrone
    N Engl J Med 358:1194-5; author reply 1195. 2008
  59. ncbi request reprint Cancer of the oropharynx
    Lisa Licitra
    START Project, European School of Oncology, Viale Beatrice d Este, 37, 20122 Milan, Italy
    Crit Rev Oncol Hematol 41:107-22. 2002
    ..Acute toxicity needs to be managed promptly. Late sequelae are less known. Treatment of such tumours requires a multidisciplinary approach within experienced centres...
  60. ncbi request reprint Folate in head and neck squamous cell cancer chemoprevention: purposely left out?
    Paolo Bossi
    J Clin Oncol 26:3463; author reply 3463-4. 2008
  61. doi request reprint Motesanib diphosphate in progressive differentiated thyroid cancer
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston 77230 1402, USA
    N Engl J Med 359:31-42. 2008
    ..Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived growth-factor receptor, and KIT...